Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective

Daniel A. Goldstein, Simon B. Zeichner

Research output: Contribution to journalArticlepeer-review

Abstract

The management of metastatic melanoma has been revolutionized in recent years with the development of both targeted therapy and immunotherapy. Although potentially extending the life expectancy for patients, these therapies also significantly increase the healthcare expenditure. In this paper, we review the monthly costs for drugs approved by the FDA since 2011. Additionally, factors that affect the cost, such as dosing strategies, biomarkers, combination therapies, and political/legislative issues, will be discussed.

Original languageEnglish
Pages (from-to)S234-S241
JournalAmerican Journal of Managed Care
Volume21
Issue number10
StatePublished - 1 Sep 2015

Fingerprint

Dive into the research topics of 'Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective'. Together they form a unique fingerprint.

Cite this